Oscar Health, Inc. (OSCR) shares soared 5.29% in pre-market trading on Tuesday, despite reporting disappointing preliminary second-quarter results for 2025. The health insurance technology company's stock movement appears to be driven by investor optimism surrounding its revised full-year outlook, overshadowing the weak quarterly performance.
According to the company's announcement, Oscar Health reported a Q2 adjusted EBITDA of -$120 million, falling short of the IBES estimate of $116.9 million. The net income for the quarter stood at -$228 million, reflecting significant losses. However, investors seem to be looking past these figures and focusing on the company's forward-looking statements.
Oscar Health revised its 2025 guidance, now anticipating revenue between $12.0 billion and $12.2 billion. The company also expects a Medical Loss Ratio of 86.0%-87.0% for the year. These projections, along with potential cost-cutting measures or strategic shifts not explicitly mentioned in the released information, may be fueling investor confidence. The pre-market rally suggests that market participants are betting on Oscar Health's long-term potential and its ability to navigate current challenges in the competitive health insurance landscape.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.